Logo image of BGMS

BIO GREEN MED SOLUTION INC (BGMS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BGMS - US23254L8761 - Common Stock

1.66 USD
-0.16 (-8.79%)
Last: 12/5/2025, 8:04:46 PM
Fundamental Rating

3

Overall BGMS gets a fundamental rating of 3 out of 10. We evaluated BGMS against 531 industry peers in the Biotechnology industry. BGMS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BGMS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGMS has reported negative net income.
In the past year BGMS has reported a negative cash flow from operations.
In the past 5 years BGMS always reported negative net income.
In the past 5 years BGMS always reported negative operating cash flow.
BGMS Yearly Net Income VS EBIT VS OCF VS FCFBGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

With a Return On Assets value of -85.49%, BGMS is not doing good in the industry: 70.62% of the companies in the same industry are doing better.
BGMS has a Return On Equity of -98.28%. This is comparable to the rest of the industry: BGMS outperforms 46.89% of its industry peers.
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROIC N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BGMS Yearly ROA, ROE, ROICBGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BGMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGMS Yearly Profit, Operating, Gross MarginsBGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

BGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BGMS has more shares outstanding than it did 1 year ago.
BGMS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BGMS Yearly Shares OutstandingBGMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10K 20K 30K
BGMS Yearly Total Debt VS Total AssetsBGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

BGMS has an Altman-Z score of -74.54. This is a bad value and indicates that BGMS is not financially healthy and even has some risk of bankruptcy.
BGMS has a worse Altman-Z score (-74.54) than 95.29% of its industry peers.
BGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -74.54
ROIC/WACCN/A
WACC8.78%
BGMS Yearly LT Debt VS Equity VS FCFBGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M 30M

2.3 Liquidity

A Current Ratio of 6.43 indicates that BGMS has no problem at all paying its short term obligations.
BGMS has a better Current ratio (6.43) than 65.91% of its industry peers.
A Quick Ratio of 5.07 indicates that BGMS has no problem at all paying its short term obligations.
BGMS's Quick ratio of 5.07 is in line compared to the rest of the industry. BGMS outperforms 57.06% of its industry peers.
Industry RankSector Rank
Current Ratio 6.43
Quick Ratio 5.07
BGMS Yearly Current Assets VS Current LiabilitesBGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

BGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.34%, which is quite impressive.
Looking at the last year, BGMS shows a quite strong growth in Revenue. The Revenue has grown by 9.46% in the last year.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%

3.2 Future

The Earnings Per Share is expected to grow by 57.16% on average over the next years. This is a very strong growth
BGMS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1049.89% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A

3.3 Evolution

BGMS Yearly Revenue VS EstimatesBGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2018 2023 2024 2025 2026 2027 20M 40M 60M 80M
BGMS Yearly EPS VS EstimatesBGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10K -20K -30K -40K -50K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BGMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGMS Price Earnings VS Forward Price EarningsBGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGMS Per share dataBGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

BGMS's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%

More info and screens

0

5. Dividend

5.1 Amount

BGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO GREEN MED SOLUTION INC

NASDAQ:BGMS (12/5/2025, 8:04:46 PM)

1.66

-0.16 (-8.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-31 2026-03-31/amc
Inst Owners0.12%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner Change11.22%
Market Cap8.13M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %8.76%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.03
Dividend Growth(5Y)-37.21%
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 100.42
P/FCF N/A
P/OCF N/A
P/B 1.15
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.49%
ROE -98.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.43
Quick Ratio 5.07
Altman-Z -74.54
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A

BIO GREEN MED SOLUTION INC / BGMS FAQ

What is the ChartMill fundamental rating of BIO GREEN MED SOLUTION INC (BGMS) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BGMS.


What is the valuation status for BGMS stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION INC (BGMS). This can be considered as Overvalued.


How profitable is BIO GREEN MED SOLUTION INC (BGMS) stock?

BIO GREEN MED SOLUTION INC (BGMS) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIO GREEN MED SOLUTION INC (BGMS) stock?

The Earnings per Share (EPS) of BIO GREEN MED SOLUTION INC (BGMS) is expected to grow by 39.49% in the next year.